Preventive Effects of Pioglitazone and Its Mechanisms in the Non-Obese Diabetic Mouse

孙曙光,周智广,张松,罗建华,孙意,张翼
DOI: https://doi.org/10.3321/j.issn:1006-6187.2007.04.016
2007-01-01
Abstract:Objective To explore the effects and mechanisms of pioglitazone on insulitis and diabetes in NOD mice. Methods Female NOD mice at 4 weeks of age were randomly devided into two groups, including 0.02% pioglitazone-mixed diet (pioglitazone group, n=26), and pioglitazone-free diet (control group, n=25). Pioglitazone was given in diet from 4 to 30 weeks of age. The accumulative diabetes incidence was followed-up to 30 weeks of age in each group of NOD mice. Pancreata were removed from NOD mice at 12 weeks of age in each group (n=15) to score insulitis severity by routine H-E staining. Their spleens were for cell culture and total RNA extraction. IL-4 and IFN-γ levels in sera and supernatants of splenocytes were measured by ELISA. Spleen IL-4 and IFN-γ mRNA levels were detected by RT-PCR. Results At 30 weeks of age, the incidence of diabetes was 80.0% (20/25) in the control group and 53.8% (14/26) in the pioglitazone group. There was a significant reduction of diabetes incidence in NOD mice treated with pioglitazone (P0.05). The insulitis score of pioglitazone group was lower than that of controls (P0.05). IL-4 levels in sera and supernatants of splenocytes and spleen IL-4 mRNA levels were higher in pioglitazone group than in control group (P0.05). The ratios of IL-4/IFN-γ in sera and supernatants of splenocytes were higher in pioglitazone group than in control group (P0.05). Conclusions Pioglitazone upregulates IL-4, induces a Th2-like response, and subsequently to some extent, lessens insulitis and reduces diabetes incidence in female NOD mice.
What problem does this paper attempt to address?